

The World's First Biomarker-based Diagnostic Test for Pancreatic Cancer Early Detection

Inviting Clinical Laboratories for LDT partnership

Early Detection of Pancreatic Cancer,

**FOR YOUR
LOVED ONES**



PAUF-detecting Diagnostic Technology **Looking for laboratory partnerships**

PAUF or Pancreatic Adenocarcinoma Up-regulated Factor is a biomarker over-expressed in over 80% of pancreatic adenocarcinoma, as well as other cancers like ovarian and prostate cancer. Overall survival for pancreatic cancer remains poor and early detection will lead to better outcomes. Our PAUF diagnostic kit allows for early detection of pancreatic cancer with fast and accurate results. Through regular screening, we want to provide peace of mind.



First-in-Class PAUF-detecting Diagnostic Kit A Powerful Tool for Screening and Detection of Pancreatic Cancer

Prestige Biopharma is developing a first-in-class diagnostic kit for the detection of Pancreatic Adenocarcinoma Upregulated Factor (PAUF).

PAUF is a distinctive tumor-specific biomarker overexpressed in over 80% of pancreatic cancer cases, associated with early progression and metastasis.

Through the successful development of the diagnostic kit on top of our novel anti-PAUF antibody PBP1510 for the treatment, we believe our efforts will significantly benefit patients with pancreatic cancer and contribute to improving human health, which is exactly what our mission 'Innovation for Life' stands for.



Pancreatic Cancer




Deadliest of solid malignancies

Late diagnosis

Chemo/Radiation resistance

Medical need: therapeutics & diagnosis

5-Year Survival Rate of Cancers



Pancreatic cancer is the seventh leading cause of cancer deaths worldwide (Rawla, Sunkara and Gaduputi, 2019). Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA and grow uncontrollably. Untreated pancreatic cancer spreads to nearby organs and blood vessels.

Despite the availability of several treatments on the market, **long-term overall survival remains poor and the need for better pancreatic cancer treatment is still unfulfilled.** Thus, early detection and diagnosis are crucial for improving patient outcomes and increasing survival rates.



Diagnosis PAUF detection in blood as pancreatic cancer screening

- Carbohydrate antigen 19-9(CA19-9) is the only approved biomarker for pancreatic cancer so far, but it has low specificity.
- The novel diagnostic method exhibits high sensitivity and specificity in detecting PAUF.
- In our preliminary data, PAUF showed a superior diagnostic power that can overcome the weaknesses of current biomarker in pancreatic cancer.

PAUF Detection Kit

| | |
|-------------------|-------------------|
| Indication | Pancreatic Cancer |
| Category | Diagnostic Kit |
| Development Stage | Discovery |



Corporate Headquarters

21 Biopolis Road, #04-24/28 Nucleos South Building, Singapore 138567
Tel : +65 6924 6535 Email : info@prestigebio.com

Innovative Discovery Center (IDC)

Prestige Biopharma IDC Co., Ltd. 2776-8, Myeongji-dong, Gangseo-gu, Busan 618-814, South Korea
Tel : +65 51 580 8000 Email : info@prestigebio.com



PRESTIGEBIOPHARMA